IO Biotech, Inc. (NASDAQ: IOBT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights [Yahoo! Finance]
IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights
IO Biotech Announces Participation in Upcoming Investor Conferences
IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study